The relationship between serum interleukin-1β and circulating CD16+ neutrophils for assessing progression-free time in advanced ovarian cancer
- Authors: Abakumova T.V.1, Antoneeva I.I.1,2, Gening S.O.3, Burkhanova E.V.1, Gening T.P.1
-
Affiliations:
- Ulyanovsk State University
- Regional Clinical Oncology Dispensary
- BestDoctor LLC
- Issue: Vol 105, No 5 (2024)
- Pages: 701-708
- Section: Theoretical and clinical medicine
- Submitted: 21.03.2024
- Accepted: 27.06.2024
- Published: 02.10.2024
- URL: https://kazanmedjournal.ru/kazanmedj/article/view/629312
- DOI: https://doi.org/10.17816/KMJ629312
- ID: 629312
Cite item
Abstract
BACKGROUND: Ovarian cancer is the most aggressive gynecological tumor with high mortality. The ambivalent, both helper and suppressive effects of neutrophils on the cells of innate and adaptive immunity determines their important immunoregulatory role in the development of malignant tumors.
AIM: Evaluation of the effect of serum interleukin-1β and circulating neutrophils CD16+ on progression-free time in advanced ovarian cancer.
MATERIAL AND METHODS: In 42 primary patients with serous ovarian adenocarcinoma (median age 54 years) with ascites and 15 patients with benign ovarian tumors (median age 60 years) admitted for examination and treatment to the Regional Clinical Oncology Dispensary before receiving neoadjuvant antitumor treatment (2015–2020), the level of interleukin-1β in the blood serum was determined using enzyme immunoassay, and the number of CD16+ neutrophils was determined by fluorescence microscopy using monoclonal antibodies. Statistical processing was performed using Statistica 13 and Jamovi 2.4.14 programs. Progression-free time analysis of patients was performed using the Cox and Kaplan–Meier regression methods.
RESULTS: It was found that the number of circulating CD16+ neutrophils in advanced ovarian cancer with ascites was lower than in benign ovarian tumors [48.0; 95% confidence interval (CI) 46.59–48.12 versus 50.0; 95% CI 48.51–49.76; p=0.017]. At the same time, the level of interleukin-1β in the blood serum in advanced ovarian cancer with ascites was higher than in benign ovarian tumors [2.52 (95% CI 2.50–3.37) versus 1.26 (95% CI 0.97–1.55) (p=0.0001)]. In multivariate Cox analysis in patients with ascites (odds ratio 4.334; 95% CI 1.83–10.23; p=0.001), both the CD16+ neutrophil count (odds ratio 0.73; 95% CI 0.62–0.86; p=0.0001) and serum interleukin-1β levels (odds ratio 1.90; 95% CI 1.41–2.57; p=0.0001) had prognostic significance for assessing progression-free time.
CONCLUSION: The number of circulating CD16+ neutrophils and serum interleukin-1β levels simultaneously affect progression-free time in advanced ovarian cancer.
Keywords
Full Text
About the authors
Tatyana V. Abakumova
Ulyanovsk State University
Author for correspondence.
Email: taty-abakumova@yandex.ru
ORCID iD: 0000-0001-7559-5246
SPIN-code: 8564-4253
Dr. Sci. (Biol.), Prof., Depart. of Physiology and Pathophysiology
Russian Federation, UlyanovskInna I. Antoneeva
Ulyanovsk State University; Regional Clinical Oncology Dispensary
Email: aii72@mail.ru
ORCID iD: 0000-0002-1525-2070
SPIN-code: 5305-5108
MD, Dr. Sci. (Med.), Prof., Depart. of Oncology and Radiation Diagnostics; Head of Depart., Gynecological Depart.
Russian Federation, Ulyanovsk; UlyanovskSnezhanna O. Gening
BestDoctor LLC
Email: sgening@bk.ru
SPIN-code: 2496-2467
MD, Cand. Sci. (Med.), Oncologist
Russian Federation, MoscowElizaveta V. Burkhanova
Ulyanovsk State University
Email: burkhanova_e@inbox.ru
ORCID iD: 0009-0008-6955-9204
SPIN-code: 4883-1274
student
Russian Federation, UlyanovskTatyana P. Gening
Ulyanovsk State University
Email: Naum-53@yandex.ru
ORCID iD: 0000-0002-5117-1382
SPIN-code: 7285-8939
Dr. Sci. (Biol.), Prof., Head of Depart., Depart. of Physiology and Pathophysiology
Russian Federation, UlyanovskReferences
- Ravindran F, Choudhary B. Ovarian cancer: Molecular classification and targeted therapy. In: Ho G, Webber K, editors. Ovarian cancer — updates in tumor biology and therapeutics. London: IntechOpen; 2021. р. 1–21. doi: 10.5772/intechopen.95967
- Ueki A, Hirasawa A. Molecular features and clinical management of hereditary gynecological cancers. Int J Mol Sci. 2020;21(24):9504. doi: 10.3390/ijms21249504
- Coleridge SL, Bryant A, Kehoe S, Morrison J. Neoadjuvant chemotherapy before surgery versus surgery followed by chemotherapy for initial treatment in advanced ovarian epithelial cancer. Cochrane Database Syst Rev. 2021;7(7):CD005343. doi: 10.1002/14651858.CD005343
- Súarez-Zaizar A, Cárdenas-Cárdenas E, Barajas-Castro YA, Cortés-Esteban P. Controversies on the treatment of ovarian cancer with dose-dense chemotherapy. Chin Clin Oncol. 2020;9(4):53. doi: 10.21037/cco-2019-oc-12
- Dosch AR, Singh S, Dai X, Mehra S, Silva IC, Bianchi A, Srinivasan S, Gao Z, Ban Y, Chen X, Banerjee S, Nagathihalli NS, Datta J, Merchant NB. Targeting tumor-stromal IL6/STAT3 signaling through IL1 receptor inhibition in pancreatic cancer. Mol Cancer Ther. 2021;20(11):2280–2290. doi: 10.1158/1535-7163.MCT-21-0083
- Baker KJ, Houston A, Brint E. IL-1 family members in cancer; Two sides to every story. Front Immunol. 2019;10:1197. doi: 10.3389/fimmu.2019.01197
- Kuan EL, Ziegler SF. A tumor-myeloid cell axis, mediated via the cytokines IL-1alpha and TSLP, promotes the progression of breast cancer. Nat Immunol. 2018;19(4):366–374. doi: 10.1038/s41590-018-0066-6
- Liu S, Lee JS, Jie C, Park MH, Iwakura Y, Patel Y, Soni M, Reisman D, Chen H. HER2 overexpression triggers an IL1α proinflammatory circuit to drive tumorigenesis and promote chemotherapy resistance. Cancer Res. 2018;78(8):2040–2051. doi: 10.1158/0008-5472.CAN-17-2761
- Dolgushin II. Neutrophil granulocytes: new faces of old acquaintances. Byulleten' sibirskoi meditsiny. 2019;18(1):30–37. (In Russ.) doi: 10.20538/1682-0363-2019-1-30-37
- Chen S, Zhang Q, Lu L, Xu C, Li J, Zha J, Ma F, Luo HR, Hsu AY. Heterogeneity of neutrophils in cancer: One size does not fit all. Cancer Biol Med. 2022;19(12):1629–1648. doi: 10.20892/j.issn.2095-3941.2022.0426
- Treffers LW, van Houdt M, Bruggeman CW, Heineke MH, Zhao XW, van der Heijden J, Nagelkerke SQ, Verkuijlen PJJH, Geissler J, Lissenberg-Thunnissen S, Valerius T, Peipp M, Franke K, van Bruggen R, Kuijpers TW, van Egmond M, Vidarsson G, Matlung HL, van den Berg TK. FcgammaRIIIb restricts antibody-dependent destruction of cancer cells by human neutrophils. Front Immunol. 2019;9:3124. doi: 10.3389/fimmu.2018.03124
- Gasparoto TH, Dalboni TM, Amôr NG, Abe AE, Perri G, Lara VS, Vieira NA, Gasparoto CT, Campanelli AP. Fcγ receptors on aging neutrophils. J Appl Oral Sci. 2021;29:e20200770. doi: 10.1590/1678-7757-2020-0770
- Alemán OR, Rosales C. Human neutrophil Fc gamma receptors: Different buttons for different responses. J Leukoc Biol. 2023;114(6):571–584. doi: 10.1093/jleuko/qiad080
- Grieshaber-Bouyer R, Nigrovic PA. Neutrophil heterogeneity as therapeutic opportunity in immune-mediated disease. Front Immunol. 2019;10:346. doi: 10.3389/fimmu.2019.00346
- Vorobjeva N, Dagil Y, Pashenkov M, Pinegin B, Chernyak B. Protein kinase C isoforms mediate the formation of neutrophil extracellular traps. Int Immunopharmacol. 2023;114:109448. doi: 10.1016/j.intimp.2022.109448
- Chang Y, Syahirah R, Wang X, Jin G, Torregrosa-Allen S, Elzey BD, Hummel SN, Wang T, Li C, Lian X, Deng Q, Broxmeyer HE, Bao X. Engineering chimeric antigen receptor neutrophils from human pluripotent stem cells for targeted cancer immunotherapy. Cell Rep. 2022;40(3):111128. doi: 10.1016/j.celrep.2022.111128
- Rakic A, Beaudry P, Mahoney DJ. The complex interplay between neutrophils and cancer. Cell Tissue Res. 2018;371(3):517–529. doi: 10.1007/s00441-017-2777-7
- Tu S, Bhagat G, Cui G, Takaishi S, Kurt-Jones EA, Rickman B, Betz KS, Penz-Oesterreicher M, Bjorkdahl O, Fox JG, Wang TC. Overexpression of interleukin-1beta induces gastric inflammation and cancer and mobilizes myeloid-derived suppressor cells in mice. Cancer Cell. 2008;14(5):408–419. doi: 10.1016/j.ccr.2008.10.011
- Masucci MT, Minopoli M, Carriero MV. Tumor associated neutrophils. Their role in tumorigenesis, metastasis, prognosis and therapy. Front Oncol. 2019;9:1146. doi: 10.3389/fonc.2019.01146
- Costa AC, Santos JMO, Gil da Costa RM, Medeiros R. Impact of immune cells on the hallmarks of cancer: A literature review. Crit Rev Oncol Hematol. 2021;168:103541. doi: 10.1016/j.critrevonc.2021.103541
- Takahashi R, Macchini M, Sunagawa M, Jiang Z, Tanaka T, Valenti G, Renz BW, White RA, Hayakawa Y, Westphalen CB, Tailor Y, Iuga AC, Gonda TA, Genkinger J, Olive KP, Wang TC. Interleukin-1β-induced pancreatitis promotes pancreatic ductal adenocarcinoma via B lymphocyte-mediated immune suppression. Gut. 2021;70(2):330–341. doi: 10.1136/gutjnl-2019-319912
- Nishida J, Momoi Y, Miyakuni K, Tamura Y, Takahashi K, Koinuma D, Miyazono K, Ehata S. Epigenetic remodelling shapes inflammatory renal cancer and neutrophil-dependent metastasis. Nat Cell Biol. 2020;22(4):465–475. doi: 10.1038/s41556-020-0491-2
- Rogers T, DeBerardinis RJ. Metabolic plasticity of neutrophils: Relevance to pathogen responses and cancer. Trends Cancer. 2021;7(8):700–713. doi: 10.1016/j.trecan.2021.04.007
- Coffelt SB, Wellenstein MD, de Visser KE. Neutrophils in cancer: Neutral no more. Nat Rev Cancer. 2016;16:431–446. doi: 10.1038/nrc.2016.52
- Shaul ME, Fridlender ZG. Neutrophils as active regulators of the immune system in the tumor microenvironment. J Leukoc Biol. 2017;102:343–349. doi: 10.1189/jlb.5MR1216-508R
- Guthrie GJ, Charles KA, Roxburgh CS, Horgan PG, McMillan DC, Clarke SJ. The systemic inflammation-based neutrophil-lymphocyte ratio: Experience in patients with cancer. Crit Rev Oncol Hematol. 2013;88:218–230. doi: 10.1016/j.critrevonc.2013.03.010
- Zhou Y, Wei Q, Fan J, Cheng S, Ding W, Hua Z. Prognostic role of the neutrophil-to-lymphocyte ratio in pancreatic cancer: A meta-analysis containing 8252 patients. Clin Chim Acta. 2018;479:181–189. doi: 10.1016/j.cca.2018.01.024
- Verschoor CP, Loukov D, Naidoo A, Puchta A, Johnstone J, Millar J, Lelic A, Novakowski KE, Dorrington MG, Loeb M, Bramson JL, Bowdish DM. Circulating TNF and mitochondrial DNA are major determinants of neutrophil phenotype in the advanced-age, frail elderly. Mol Immunol. 2015;65(1):148–156. doi: 10.1016/j.molimm.2015.01.015
- Fossati G, Moots RJ, Bucknall RC, Edwards SW. Differential role of neutrophil Fcgamma receptor IIIB (CD16) in phagocytosis, bacterial killing, and responses to immune complexes. Arthritis Rheum. 2002;46(5):1351–1361. doi: 10.1002/art.10230